Opinions
Jim Cramer - Mad Money
Emergent BioSolutions
EBS-N
COMMENT
Mar 03, 2021
EBS is helping to produce Covid vaccines. Despite this, the stock has been hammered 25% from recent high, a victim of the current rotation favouring reopening stocks and dumping other sectors. The stock has gotten too cheap at 10x earnings; it's a growth stock.
$94.730
Stock price when the opinion was issued
biotechnology
pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
BUY
Instead of buying a single vaccine-making pharma, consider this. They have an established vaccine business and are working on plasma-based treatments for Covid. They also have a big contract manufacturing business of vaccines with JNJ, AZN and Novavax. This has fallen $40 from its August peak. But last night they issued bullish future numbers for this year, and the stock jumped 4.7% today. More upside to come.
biotechnology
pharmaceutical
SELL
A disaster. He feels bad for J&J that they ever signed a contract with them.
biotechnology
pharmaceutical
Advertising